LONDON, 2025 — Claritas Intelligence has published its latest market intelligence report on the global medical cold gel market, sizing the category at USD 1.21 billion in 2025 and projecting growth to USD 1.8 billion by 2033. The report's base case carries a 5.2% CAGR across the 2025–2033 forecast period, with demand anchored to rising surgical volumes, multimodal post-operative analgesia protocols, and expanding over-the-counter topical analgesic adoption.
The primary demand driver is post-surgical pain management. Post-operative guidelines increasingly favor non-opioid adjuncts, and cold therapy gel occupies a well-established role in those protocols — both as a conductive medium in cryotherapy and as a standalone menthol-based counterirritant. Ochsner Health System is actively recruiting for two comparative effectiveness trials (NCT07023185 and NCT07516327), studying cold-and-compression outcomes in total knee arthroplasty and rotator cuff repair, with start dates in December 2025 and March 2026 respectively. Outcomes from those trials are expected to directly shape institutional formulary decisions. An emerging secondary demand pathway is peripheral neuropathy: Koç University's NCT06488963 (recruiting since January 2023) is evaluating cold therapy devices in peripheral neuropathy patients, a large global population where topical cold gel could function as a non-pharmacological adjunct. A positive primary endpoint read could open labeling expansion and NDA/sNDA filing activity not currently reflected in consensus estimates.
North America holds the largest regional share at approximately 38% of global revenue. U.S. per-capita health expenditure of USD 13,473.19 (2023) and a health spend-to-GDP ratio of 16.69% sustain willingness-to-pay for both branded Rx and premium OTC cold gel formats. McKesson Corporation, which reported FY2026 revenue of USD 403.43 billion, remains the dominant U.S. distribution channel partner across retail and institutional cold gel SKUs. Asia Pacific is the report's fastest-growing region, carrying an estimated segment CAGR of 6.8% (Claritas model). China's per-capita health spend of USD 763.38 (2023) sits well below U.S. and EU levels, indicating a substantial access-expansion runway; Japan's health spending at 10.74% of GDP signals a more mature but demographically driven demand base. India, with per-capita health spend of USD 84.69 (2023), presents a volume-over-value growth profile. Regional aging trends documented in GBD 2021 forecasts project meaningful expansion of the chronic musculoskeletal pain population through 2033, reinforcing the regional growth thesis.
Market concentration is low: no single branded manufacturer commands more than 15% of global revenue share (Claritas model). Key participants include Performance Health International (Biofreeze), Hisamitsu Pharmaceutical (Salonpas), Rohto Pharmaceutical, Mentholatum, Gebauer Company, Mueller Sports Medicine, and Icy Hot (Chattem, a Sanofi company), alongside distribution-oriented players such as Cardinal Health and Patterson Companies (Patterson Medical). This fragmentation creates acquisition optionality for distributors pursuing vertical integration while simultaneously exposing branded incumbents to private-label commoditization pressure.
"The consensus view on medical cold gel underweights a structural substitution risk: purpose-built cold-and-compression devices are being studied as integrated interventions, not as complements to gel. If Ochsner's TKA and rotator cuff trials favor device-only protocols, hospital value analysis committees will have clinical cover to de-list single-use gel pouches from surgical bundles. That scenario is not priced into most market models — and it makes channel diversification, particularly the direct-to-patient e-commerce shift, a more urgent strategic priority than it might otherwise appear." — Ananya Sharma, Senior Analyst, Claritas Intelligence
About Claritas Intelligence: Claritas Intelligence is a global market intelligence publisher serving strategy, investment, and product teams across pharmaceuticals, medtech, and adjacent industries. The firm's research combines proprietary demand modelling with primary regulatory and clinical data sourcing to deliver analysis that decision-makers can act on.
The full analysis, including segmentation, regional breakdowns, forecasts, and company profiles, is available in the Medical Cold Gel Market Report.
“The global medical cold gel market is estimated at USD 1.21 billion in 2025 and projected to reach USD 1.8 billion by 2033 at a 5.2% CAGR, per new Claritas Intelligence research.”
Ananya Sharma
Senior Research Analyst – Healthcare & Life Sciences